Home/Federal Circuit/Biogen Ma Inc. v. Emd Serono, Inc.

Biogen Ma Inc. v. Emd Serono, Inc.

Procedural entryThis page is a short order in Biogen Ma Inc. v. Emd Serono, Inc.. Read the opinion of the Court — 976 F.3d 1326 →
Court of Appeals for the Federal Circuit·Decided November 20, 2020·No. 19-1133·Unpublished

Opinion

Case: 19-1133 Document: 98 Page: 1 Filed: 11/20/2020

United States Court of Appeals for the Federal Circuit

November 20, 2020

ERRATA

Appeal No. 2019-1133

BIOGEN MA INC., Plaintiff -Appellee

v.

EMD SERONO, INC., PFIZER INC., Defendants-Appellants

BAYER HEALTHCARE PHARMACEUTICALS INC., NOVARTIS PHARMACEUTICALS CORPORATION, Defendants

Decided: September 28, 2020 Precedential Opinion

Please make the following changes:

On page 8, lines 17–20, change “emphasized that whereas the attached carbohydrate groups in native IFN-β protein were glycosolated, the attached carbohydrate groups in recombinant IFN-β were not glycosolated,” to —explained that the glycosylation patterns in native IFN-β and recombinant IFN-β were different,—.

Free access — add to your briefcase to read the full text and ask questions with AI

Biogen Ma Inc. v. Emd Serono, Inc., (Fed. Cir. 2020).

Biogen Ma Inc. v. Emd Serono, Inc. (Biogen Ma Inc. v. Emd Serono, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.